Pain medication at ictus of subarachnoid hemorrhage-the influence of one-time acetylsalicylic acid usage on bleeding pattern, treatment course, and outcome: a matched pair analysis.


Journal

Neurosurgical review
ISSN: 1437-2320
Titre abrégé: Neurosurg Rev
Pays: Germany
ID NLM: 7908181

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 24 03 2018
accepted: 18 06 2018
revised: 12 06 2018
pubmed: 24 6 2018
medline: 7 8 2019
entrez: 24 6 2018
Statut: ppublish

Résumé

Acetylsalicylic acid (ASA) is a well-known and widely used analgesic for acute pain. Patients with acute headache due to subarachnoid hemorrhage (SAH) are inclined to take ASA in this situation. Due to the antithrombotic effects, ASA intake is related to higher bleeding rates in case of hemorrhage or surgical treatment. Between January 2006 and December 2016, 941 patients without continuous antithrombotic or anticoagulant medication were treated due to SAH in our institution. Fourteen of them (1.5%) had taken ASA as a single dose because of headache within 24 h before hospital admission. A matched pair analysis was performed. Admission status was good in 93% of patients with one-time use of ASA (OTA), but only in 59% of all other patients (p < 0.01). Bleeding pattern did not differ, but half of the patients with OTA had no identifiable bleeding source; this rate was significantly lower in the rest of the patients (p < 0.005). Aneurysm treatment and related complications did not differ between both groups. Cerebral vasospasm was more often only mild and rates of cerebral infarctions were lower in the OTA group but not on a significant level. Eighty-six percent of the OTA group and 84% (p = 0.8) of the matched pair control group reached favorable outcome according to mRS 6 months after SAH. Patients with OTA in case of SAH are usually in good clinical condition and bleeding pattern does not differ. In half of the patients with OTA, no bleeding source was detectable. In the case of aneurysm treatment, related complications did not differ and most of the patients reached favorable outcome. In the case of aneurysm treatment procedure, OTA does not influence treatment course and should not influence treatment decisions.

Identifiants

pubmed: 29934857
doi: 10.1007/s10143-018-1000-y
pii: 10.1007/s10143-018-1000-y
doi:

Substances chimiques

Anticoagulants 0
Fibrinolytic Agents 0
Aspirin R16CO5Y76E

Types de publication

Journal Article

Langues

eng

Pagination

531-537

Références

Stroke. 2003 Sep;34(9):2285-9
pubmed: 12881605
J Neurosurg. 2004 Dec;101(6):921-5
pubmed: 15597751
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD000277
pubmed: 15674871
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD006184
pubmed: 17943892
Surg Neurol. 2009 May;71(5):566-71; discussion 571,571-2,572
pubmed: 18617230
Stroke. 2011 Nov;42(11):3156-62
pubmed: 21980208
Br J Anaesth. 2012 Sep;109(3):315-29
pubmed: 22879655
Crit Care. 2013 Mar 21;17(2):R53
pubmed: 23514619
Neurosurgery. 2013 Aug;73(2):201-8
pubmed: 23632760
World Neurosurg. 2014 Jan;81(1):e2-3
pubmed: 24120928
Neurosurg Rev. 2014 Oct;37(4):653-9
pubmed: 25011406
Neurosurgery. 2014 Nov;75(5):530-5; discussion 534-5
pubmed: 25072111
J Neurosurg. 2015 Mar;122(3):663-70
pubmed: 25526276
Neurosurgery. 2015 May;76(5):540-50; discussion 550-1
pubmed: 25635884
Cerebrovasc Dis. 2015;39(5-6):332-42
pubmed: 25967073
World Neurosurg. 2015 Dec;84(6):1653-9
pubmed: 26183133
World Neurosurg. 2016 Apr;88:488-96
pubmed: 26498398
J Neurosurg. 2016 Jun;124(6):1731-7
pubmed: 26566212
J Neurosurg. 2017 Feb;126(2):537-547
pubmed: 27058205
Neurocrit Care. 2017 Aug;27(1):11-16
pubmed: 28000128
Curr Cardiol Rep. 2017 Feb;19(2):18
pubmed: 28213669
Stroke. 2017 May;48(5):1210-1217
pubmed: 28341753
World Neurosurg. 2018 May;113:e122-e128
pubmed: 29408591
Neurosurgery. 1980 Jan;6(1):1-9
pubmed: 7354892
J Neurosurg. 1995 Jun;82(6):945-52
pubmed: 7760196

Auteurs

Markus Bruder (M)

Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany. markus.bruder@kgu.de.

Sepide Kashefiolasl (S)

Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany.

Fee Keil (F)

Department of Neuroradiology, Goethe University, Frankfurt am Main, Germany.

Nina Brawanski (N)

Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany.

Sae-Yeon Won (SY)

Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany.

Volker Seifert (V)

Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany.

Juergen Konczalla (J)

Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH